What to do if GLP-1 Medications Reduce Libido
It’s a difficult question to even ask. Can weight-loss wonder drugs like Ozempic and Wegovy also reduce libido? There’s been a wave of fascination, almost a collective obsession, with this new class of GLP-1 drugs, often described as revolutionary. One topic, however, isn’t being discussed nearly enough. It sits quietly beneath the surface, weighed down […]
Is Rybelsus the same as semaglutide?
There has been a tidal wave of interest in the new “wonder drugs” that are based on chemicals called glucagon-like peptide-1 receptor agonists (GLP-1RA), which have revolutionized treatments of a wide range of potentially serious diseases. Many people are now familiar with the common terms associated with these new treatments, such as Ozempic, Mounjaro, semaglutide […]
Exploring treatment options for fatty liver disease in adults over 40
Metabolic dysfunction–associated steatotic liver disease (MASLD), previously known as nonalcoholic fatty liver disease (NAFLD), is becoming one of the most common causes of chronic liver illness among adults over 40. It is strongly linked to obesity, type 2 diabetes, high blood pressure, and high cholesterol. When ignored, MASLD can progress to liver scarring, cirrhosis, and […]
Serena Williams Shows Us the Power of Strength in Self-Care
Watching the finals of the US Tennis Open a few weeks ago, my young niece asked, “How big is the prize?” In my ignorance, I guessed, “It’s a lot of money – probably a million dollars!” My older nephew quickly jumped into the conversation with his iPhone in hand – “No, you’re wrong (implying – […]
GLP-1 Medications and Aging: Benefits and Risks for Older Adults
GLP-1 medications like Ozempic and Mounjaro are gaining popularity among older adults not only for managing diabetes but also for their potential anti-aging effects. But alongside the benefits, there are real risks, especially for those over 65. Understanding both sides is key to making informed decisions that support healthy aging. GLP-1 drugs revolutionized the world […]
Talking About Losing Weight? What the Ads About Weight-loss Drugs Aren’t Telling You!
GLP-1 drugs like Ozempic and Mounjaro are everywhere – on TV, online, and even in celebrity interviews. But what this chatter about losing weight rarely explains are the real-world challenges: side effects, access, cost, and what happens when people stop taking them. Here’s what people need to know before getting swept up in the hype. […]
Common GLP-1 Side Effects Made Simple
Drugs like Ozempic, Wegovy, Zepbound, and Mounjaro have changed the way doctors manage type 2 diabetes and obesity. These medications, called GLP-1 receptor agonists, help the body produce more insulin after meals, slow down digestion, and reduce appetite. The results can be dramatic, including weight loss, improved blood sugar control, and a reduced risk of heart disease. But there’s […]
Zepbound and the Future of Weight Loss
Most people are familiar with the bundle of medications that have hit our shelves over the past five or so years, which have either directly or indirectly revolutionized the whole field of weight loss. We can now introduce the latest, and in many ways the most exciting product in this field, which is Zepbound. In […]
Wegovy is Being Tested to Treat Severe Fatty Liver Disease
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly called non-alcoholic fatty liver disease (NASH), affects nearly one-third of the US population (over 100 million people). Obesity is thought to be the most common cause. In some cases, MASLD can develop into a more serious condition called metabolic dysfunction-associated steatohepatitis (MASH). Both conditions develop when the liver […]
The Link Between Sleep and Healthy Weight
Is this you? It’s late at night, and suddenly a bowl of pasta sounds like the perfect idea. Or maybe you wake up for a quick bathroom trip and find yourself craving a midnight snack. Is it normal? No, but it is surprisingly common, and the mismanagement of sleep and nutrition could affect not just […]
